Support Weight loss Medications- Tirzepatide

Dual GIP and GLP-1 receptor agonist for diabetes and weight management

15-22%

Average Weight Loss

Clinically Proven Results

Exceptional Weight Loss

Clinical trials show 15-22% average weight loss - more than any other medication

Heart Health Benefits

Improves cardiovascular health while managing diabetes effectively

FDA Approved

Latest breakthrough technology approved for both diabetes and weight management

Why Choose Tirzepatide?

Tirzepatide represents the latest breakthrough in weight management and diabetes treatment. As a novel dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist, it offers unprecedented results for patients seeking effective, long-term solutions.

Real Patient Success:

"I lost 45 pounds in 6 months with Tirzepatide. My energy is back, my diabetes is under control, and I feel like myself again." - Sarah M.

Mechanism of Action

  • GLP-1 Receptor Activation: Stimulates insulin secretion in a glucose-dependent manner, suppresses glucagon release, and slows gastric emptying

  • GIP Receptor Activation: Enhances insulin sensitivity and may have direct effects on fat metabolism

  • Appetite Regulation: Acts on brain receptors to reduce appetite and food intake

  • Gastric Motility: Slows gastric emptying, leading to increased satiety

Transformation Results

Diabetes Management:

  • Significant reduction in HbA1c levels

  • Improved glycemic control

  • Low risk of hypoglycemia

  • Cardiovascular benefits

Weight Management Success:

  • Average weight loss of 15-22% in clinical trials

  • Sustained weight reduction

  • Improved body composition

  • Reduction in waist circumference

Clinical Trial Highlights:

In the SURMOUNT trials, patients achieved an average of 20.9% weight loss at the highest dose - results that exceeded all expectations and set new standards in weight management therapy.

Dosing and Administration

Route: Subcutaneous injection once weekly
Starting Dose: 2.5 mg once weekly for 4 weeks
Maintenance Doses:

  • 5 mg once weekly (minimum effective dose)

  • 7.5 mg once weekly

  • 10 mg once weekly

  • 12.5 mg once weekly

  • 15 mg once weekly (maximum dose)

Injection Sites: Thigh, abdomen, or upper arm. Rotate injection sites weekly.

Side Effects

Common (≥5%):

  • Nausea (12-18%)

  • Diarrhea (12-16%)

  • Vomiting (6-12%)

  • Constipation (6-7%)

  • Abdominal pain (6-9%)

  • Injection site reactions

Serious (Rare):

  • Pancreatitis

  • Gallbladder disease

  • Kidney problems

  • Severe hypoglycemia (when combined with insulin/sulfonylureas)

  • Thyroid C-cell tumors (theoretical risk)

Contraindications & Precautions

Contraindications:

  • Personal or family history of medullary thyroid carcinoma

  • Multiple Endocrine Neoplasia syndrome type 2

  • Known hypersensitivity to tirzepatide

Use with Caution:

  • History of pancreatitis

  • Severe renal impairment

  • Diabetic retinopathy

  • Pregnancy and breastfeeding

Disclaimer: I.R.I.S.E. Inc. provides transformation coaching, meal plans, and products—including the 12-Week Transformation Program and the 12-Week Transformation Enhanced Program—for informational and educational purposes only. This content is not intended to replace medical advice, diagnosis, or treatment. Always consult with your physician or a qualified healthcare provider regarding any medical questions or before beginning a new wellness program. Disclaimer: No Medical Advice

Privacy & HIPAA: We maintain a secure platform, and all personal health information is protected in compliance with HIPAA regulations. Clients are required to sign both a HIPAA Consent Form and a Non-Disclosure Agreement (NDA). All materials, plans, and content provided by I.R.I.S.E. are for personal use only and must not be copied, duplicated, or shared outside of the client receiving services.

Results Disclaimer: Individual weight-loss results vary based on effort, commitment, and adherence to the program. I.R.I.S.E. Inc. makes no guarantees of specific outcomes.

📧 For questions or support, contact us at i.r.i.s.e615@gmail.com